ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions
View by Date

Sunday, November 5, 2017

9:00AM-11:00AM
Abstract Number: 287
Anti-TNF Agents Induce Alternative Macrophages
Innate Immunity and Rheumatic Disease Poster I
9:00AM-11:00AM
Abstract Number: 724
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I
9:00AM-11:00AM
Abstract Number: 12
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Analysis: Pregnancy Outcomes Since Inception
Antiphospholipid Syndrome Poster
9:00AM-11:00AM
Abstract Number: 8
Antiphospholipid Syndrome Leukocytes Demonstrate Increased Adhesive Potential:  a Search for Novel Therapeutic Targets
Antiphospholipid Syndrome Poster
9:00AM-11:00AM
Abstract Number: 760
Antisense Long Noncoding RNA HAND2-AS1 and OTUD6B-AS1 Have Important Roles in the Pathogenesis of Systemic Sclerosis
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I
9:00AM-11:00AM
Abstract Number: 791
Aortic Dilatation in Patients with Large Vessel Vasculitis: A Longitudinal Case Control Study Using Positron Emission Tomography/Computed Tomography
Vasculitis Poster I: Large Vessel Vasculitis
9:00AM-11:00AM
Abstract Number: 689
Apolipoprotein L1 Risk Variants Associate with Hypertension and Nephritis Progression Despite Lower dsDNA Titers in Ghanaian Systemic Lupus Erythematous Patients
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes
9:00AM-11:00AM
Abstract Number: 764
Application of a Novel Computational Approach to Identify New Targets and Pathways for Therapeutic Intervention in Scleroderma
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I
9:00AM-11:00AM
Abstract Number: 268
Applications of Salivary Gland Ultrasonography in Sjögren Syndrome and Sicca Symptoms: A Single Center Experience
Imaging of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 173
Applying Urine Proteomics for Discovery of Lupus Nephritis Damage Biomarkers in a Pediatric Cohort
Genetics, Genomics and Proteomics Poster I
9:00AM-11:00AM
Abstract Number: 487
ARE ANTI-Citrullinated Protein Antibody Levels Associated with Periodontal Disease in Rheumatoid Arthritis?
Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I
9:00AM-11:00AM
Abstract Number: 648
Are Choline Metabolites Associated with Inflammation in Psoriatic Arthritis?
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I
9:00AM-11:00AM
Abstract Number: 236
Are Magnetic Resonance Imaging Features of the Hand Associated with Patient Reported Physical Function, Global Assessment of Disease Activity, Pain and Health Related Quality of Life in Rheumatoid Arthritis in Clinical Remission? – Longitudinal Results from an Observational Cohort
Imaging of Rheumatic Diseases Poster I
9:00AM-11:00AM
Abstract Number: 144
Are RA Patients at a Higher Risk for Car Accidents?
Epidemiology and Public Health Poster I: Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 638
Are There Clinical Demographic or Subclinical Ultrasonographic Data That Can Predict Flare in Psoriatic Arthritis Patients during a Phase of Minimal Disease Activity after Spacing of Anti-TNF Blockers Injections?
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I
  • «Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology